These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15298733)

  • 1. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation.
    Esumi H; Lu J; Kurashima Y; Hanaoka T
    Cancer Sci; 2004 Aug; 95(8):685-90. PubMed ID: 15298733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy.
    Yu DH; Macdonald J; Liu G; Lee AS; Ly M; Davis T; Ke N; Zhou D; Wong-Staal F; Li QX
    PLoS One; 2008; 3(12):e3951. PubMed ID: 19079611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effect of pyrvinium pamoate on uveal melanoma cells involves blocking of Wnt/β-catenin pathway.
    Zheng L; Liu Y; Pan J
    Acta Biochim Biophys Sin (Shanghai); 2017 Oct; 49(10):890-898. PubMed ID: 28981601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer.
    Xu W; Lacerda L; Debeb BG; Atkinson RL; Solley TN; Li L; Orton D; McMurray JS; Hang BI; Lee E; Klopp AH; Ueno NT; Reuben JM; Krishnamurthy S; Woodward WA
    PLoS One; 2013; 8(8):e71508. PubMed ID: 24013655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
    Feng J; Jiang W; Liu Y; Huang W; Hu K; Li K; Chen J; Ma C; Sun Z; Pang X
    Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of pyrvinium pamoate on colon cancer cell viability.
    Wiegering A; Uthe FW; Hüttenrauch M; Mühling B; Linnebacher M; Krummenast F; Germer CT; Thalheimer A; Otto C
    Int J Colorectal Dis; 2014 Oct; 29(10):1189-98. PubMed ID: 25060218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma.
    Hatamipour M; Jaafari MR; Zangui M; Shakour N; Sahebkar A
    Anticancer Agents Med Chem; 2021; 21(17):2379-2384. PubMed ID: 33596812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrvinium pamoate inhibits cell proliferation through ROS-mediated AKT-dependent signaling pathway in colorectal cancer.
    Zheng W; Hu J; Lv Y; Bai B; Shan L; Chen K; Dai S; Zhu H
    Med Oncol; 2021 Feb; 38(2):21. PubMed ID: 33554313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation.
    Lu J; Kunimoto S; Yamazaki Y; Kaminishi M; Esumi H
    Cancer Sci; 2004 Jun; 95(6):547-52. PubMed ID: 15182438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrvinium targets autophagy addiction to promote cancer cell death.
    Deng L; Lei Y; Liu R; Li J; Yuan K; Li Y; Chen Y; Liu Y; Lu Y; Edwards CK; Huang C; Wei Y
    Cell Death Dis; 2013 May; 4(5):e614. PubMed ID: 23640456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrvinium Pamoate Induces Cell Apoptosis and Autophagy in Colorectal Cancer.
    Zheng W; Chen K; Lv Y; Lao W; Zhu H
    Anticancer Res; 2024 Mar; 44(3):1193-1199. PubMed ID: 38423653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Anticancer Drug Effects on Pancreatic Cancer Cells under Glucose-Depleted Conditions Using Intracellular and Extracellular Amino Acid Metabolomics.
    Tomita R; Todoroki K; Hayama T; Yoshida H; Fujioka T; Nakashima M; Yamaguchi M; Nohta H
    Biol Pharm Bull; 2018; 41(2):220-228. PubMed ID: 29386482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases through Effects on Lipid Anabolism.
    Dattilo R; Mottini C; Camera E; Lamolinara A; Auslander N; Doglioni G; Muscolini M; Tang W; Planque M; Ercolani C; Buglioni S; Manni I; Trisciuoglio D; Boe A; Grande S; Luciani AM; Iezzi M; Ciliberto G; Ambs S; De Maria R; Fendt SM; Ruppin E; Cardone L
    Cancer Res; 2020 Oct; 80(19):4087-4102. PubMed ID: 32718996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3.
    Harada Y; Ishii I; Hatake K; Kasahara T
    Cancer Lett; 2012 Jun; 319(1):83-8. PubMed ID: 22210382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel role of pyrvinium in cancer therapy.
    Momtazi-Borojeni AA; Abdollahi E; Ghasemi F; Caraglia M; Sahebkar A
    J Cell Physiol; 2018 Apr; 233(4):2871-2881. PubMed ID: 28500633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of casein kinase 1α activator pyrvinium pamoate on erythrocyte ion channels.
    Kucherenko Y; Zelenak C; Eberhard M; Qadri SM; Lang F
    Cell Physiol Biochem; 2012; 30(2):407-17. PubMed ID: 22814238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy.
    Izuishi K; Kato K; Ogura T; Kinoshita T; Esumi H
    Cancer Res; 2000 Nov; 60(21):6201-7. PubMed ID: 11085546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible repurposing of pyrvinium pamoate for the treatment of mesothelioma: A pre-clinical assessment.
    Barbarino M; Cesari D; Intruglio R; Indovina P; Namagerdi A; Bertolino FM; Bottaro M; Rahmani D; Bellan C; Giordano A
    J Cell Physiol; 2018 Sep; 233(9):7391-7401. PubMed ID: 29659015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.
    Schultz CW; McCarthy GA; Nerwal T; Nevler A; DuHadaway JB; McCoy MD; Jiang W; Brown SZ; Goetz A; Jain A; Calvert VS; Vishwakarma V; Wang D; Preet R; Cassel J; Summer R; Shaghaghi H; Pommier Y; Baechler SA; Pishvaian MJ; Golan T; Yeo CJ; Petricoin EF; Prendergast GC; Salvino J; Singh PK; Dixon DA; Brody JR
    Mol Cancer Ther; 2021 Nov; 20(11):2166-2176. PubMed ID: 34413127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.
    Lim M; Otto-Duessel M; He M; Su L; Nguyen D; Chin E; Alliston T; Jones JO
    ACS Chem Biol; 2014 Mar; 9(3):692-702. PubMed ID: 24354286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.